Nurix Therapeutics, Inc. · NASDAQ:NRIX
Nurix Therapeutics — Merger or Acquisition (June 2026)
19 slides from Nurix Therapeutics's merger presentation, Jun 8, 2026
Slide 1: Unlocking the Full Potential of Bexobrutideg: A Global Collaboration Between Nurix and Roche
Unlocking the Full Potential of Bexobrutideg A Global Collaboration Between Nurix and Roche June 8, 2026 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words “anticipate,”
Slide 3: Welcome and Introductions
Welcome and Introductions 3 Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Board Director Nurix Therapeutics Jason Kantor, Ph.D. Chief Business Officer Nurix Therapeutics John Northcott Chief Commercial Officer Nurix Therapeutics Hans van Houte Chief Financial Officer Nurix Ther
Slide 4: Unlocking the Full Potential of Bexobrutideg
Unlocking the Full Potential of Bexobrutideg One asset. Multiple diseases. Global impact. 4 Potential best-in-class BTK-targeted therapy Opportunity across multiple therapeutic areas Robust clinical data in broad CLL population Leader in targeted protein degradation Proven leader in oncology, immuno
Slide 5: A Transformative Partnership to Maximize the Value of Bexobrutideg
A Transformative Partnership to Maximize the Value of Bexobrutideg Accelerating and expanding the potential of bexobrutideg through a shared ambition to transform patient outcomes across oncology, immunology and neurology 5 Co-development and co-commercialization in the U.S. accelerates Nurix’s evol
Slide 6: Bexobrutideg: Targeted Protein Degradation of BTK with Potential Best-in-Class Profile
Bexobrutideg: Targeted Protein Degradation of BTK with Potential Best-in-Class Profile 6 Eliminates both the enzymatic and scaffolding activities of BTK Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrated robust clinical act
Slide 7: Bexobrutideg Demonstrates High Response Rates and Durable Disease Control in Heavily Pre-Treated CLL
Bexobrutideg Demonstrates High Response Rates and Durable Disease Control in Heavily Pre-Treated CLL ORR in CLL (95% CI 69–92) O B J E C T I V E R E S P O N S E R A T E 1 83% • Population: response-evaluable CLL patients (n=47) • Median prior lines: 4 prior therapies before bexdeg • Best response: 2
Slide 8: Bexobrutideg: A Complementary Strategic and Portfolio Fit with Roche
8 A global leader in oncology, immunology and neurology with expertise and capabilities in establishing B-cell targeted therapies as a new standard of care across therapeutic areas Bexobrutideg: A Complimentary Strategic and Portfolio Fit with Roche At Roche, our goal is to create new possibilities
Slide 9: Our Mission
9 OUR MISSION To establish degrader-based medicines at the forefront of patient care
Slide 10: Joint Development Plan: A Comprehensive Multi-Indication Program
Neurology Joint Development Plan A Comprehensive Multi-Indication Program Oncology Immunology 10
Slide 11: A Robust Clinical Development Plan in Malignant Hematology
A Robust Clinical Development Plan in Malignant Hematology CLL Chronic Lymphocytic Leukemia Planned DAYBreak CLL-306 | Phase 3 – 2L+ vs Pirtobrutinib Planned Phase 3 – 2L Combination Phase 1b/2 Study – 1L+ Basket Combination Study 11 MCL Mantle Cell Lymphoma WM Waldenström macroglobulinemia Planned
Slide 12: Expanding Bexobrutideg Across Immunology and Neurological Indications
Expanding Bexobrutideg Across Immunology and Neurological Indications CSU Chronic Spontaneous Urticaria Planned Phase 2 Rationale: • BTK is a critical regulator of FcεRI-driven activation in mast cells and basophils and a central node controlling B cell inflammatory pathways • Bexobrutideg more pote
Slide 13: Nurix: Fully Integrated Multi-Asset Biopharmaceutical Company in Oncology
Program Indication / Line of therapy Preclinical Phase 1 Phase 2 Phase 3 Partner Bexobrutideg BTK degrader CLL 2L+ Monotherapy CLL 3L+ triple-exposed, monotherapy CLL / NHL 1L+ Basket combination Zelebrudomide BTK-IKZF degrader B-cell malignancies Wholly Owned NX-1607 CBL-B inhibitor Solid tumor Rel
Slide 14: Nurix: Fully Integrated Biopharma Company in Immunology and Neurology
Nurix: Accelerating Evolution Into a Fully Integrated Multi-Asset Biopharmaceutical Company in Immunology and Neurology 14 IM M UN O LO G Y & N EU RO LO G Y Program Indication / Line of therapy IND enabling Phase 1 Phase 2 Phase 3 Partner Bexobrutideg BTK degrader Chronic spontaneous urticaria Multi
Slide 15: Initial Bexobrutideg Development Plan Targets Multibillion-Dollar Market Opportunities
15 ~$26B projected 2030 sales Multiple Sclerosis Source for projected 2030 sales for CLL, WM, Urticaria and Multiple Sclerosis: Evaluate Pharma (accessed May 2026) CSU sales estimates assume 70-80% of Urticaria sales can be attributed to CSU Source for projected 2030 sales for MCL: Clarivate DRG Dis
Slide 16: Nurix's Partnership Model – Creating a Fully Integrated Biopharma Company
Nurix’s Partnership Model – Creating a Fully Integrated Biopharma Company Current Collaborations PARTNER COLLABORATION PAYMENTS** LEAD ASSET $135M IRAK4 degrader Nurix retains 50/50 U.S. profit share and co-promotion rights (subject to one program veto right by Gilead) • Unlocking the global develop
Slide 17: Combining Nurix's Leadership in Targeted Protein Degradation With Roche's Capabilities
Combining Nurix’s Leadership in Targeted Protein Degradation With Roche’s Global Development and Commercial Capabilities To accelerate development, expand indications & bring bexobrutideg to patients worldwide For Bexobrutideg Unlocks a comprehensive global development strategy across oncology, immu
Slide 18: Question and Answer Session
Question and Answer Session 18 z Bringing together complementary capabilities with a shared ambition to unlock the full potential of BTK degradation for patients worldwide.
Slide 19: Nurix
NURIX
Nurix Therapeutics — Merger or Acquisition (June 2026) on 6ix